NBIX
Neurocrine Biosciences Inc
145.50$
+0.9%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -41.7% | +5.5% | -50.4% | +144.6% | +53.5% | -73.3% | +57.4% | +123.0% | +70.7% | -62.5% | -6.4% | – | |
| – | +3.6% | +8.8% | +17.7% | -11.0% | +9.2% | +7.0% | -3.9% | +5.5% | -2.6% | -2.7% | +239.7% | – | |
| – | -20.3% | +16.8% | -3.1% | -3.7% | +60.0% | -20.5% | +0.0% | +1.7% | +9.1% | -2.4% | +13.6% | – | |
| – | -216.7% | – | – | – | +2,043.2% | -125.1% | – | – | – | -102.5% | – | – | |
| – | -28.9% | +107.4% | +3.6% | -30.2% | -9.9% | +46.6% | +16.8% | +5.6% | -81.8% | +279.2% | -14.3% | – | |
| – | +107.4% | -72.7% | -48.7% | – | -376.5% | – | -304.2% | +578.3% | -73.1% | +856.9% | -73.3% | – | |
| – | – | – | – | – | – | -50.0% | -88.2% | -100.0% | – | – | -77.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +88.3% | +97.5% | -519.2% | – | -1,198.5% | -59.3% | -97.2% | – | -18.2% | -330.8% | – | – | |
| – | -131.9% | – | -276.7% | – | -155.4% | – | – | +9.0% | +389.2% | -219.8% | – | – | |
| – | -42.2% | +0.8% | -55.5% | +182.8% | +56.9% | -77.0% | +65.4% | +139.4% | +82.4% | -65.0% | -5.9% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.